Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NantKwest nets $222mm in IPO

Executive Summary

NantKwest Inc (formerly Conkwest; natural killer (NK) cells for cancer, infectious disease, and immune disorders) netted $222mm in its IPO of 9.5mm shares (including the overallotment) at $25, above its planned terms of 7mm shares for $20-23. Existing stockholders including Franklin Templeton and NantKwest CEO Patrick Soon-Shiong, MD, agreed to buy $55.5mm in IPO shares. In a separate private placement, NantKwest raised $17mm from Celgene.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies